Sensorion Receives European Authorization to Initiate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
96
Sensorion Receives European Authorization to Initiate SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss
  • Sensorion’s 2nd European Voluntary Harmonization Procedure Application Approval  
  • International Multicenter Phase 2 with SENS-401 for Treating Sudden Sensorineuronal Hearing Loss in Adults to Start

MONTPELLIER, France, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Sensorion ( FR 0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases, today announces that the HMA (Heads of Medicines Agencies, a European network of the Heads of the National Competent Authorities) approved the company’s Volunturary Harmonization Procedure (VHP) application to initiate a Phase 2 clinical trial for SENS-401 in the treatment of sudden sensorineural hearing loss (SSNHL) in adults.

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company aims for a study start (first patient in) in Q4 2018, and interim topline data in Q4 2019. Principal investigator is Prof. Dr. Arne Ernst, Professor and Chairman, Dept. Otorhinolaryngology at UKB, the teaching hospital of the Berlin Charité Medical University and the Alice Solomon Hochschule Clinical Centre, and Past/Honorary Chairman of the German Society of Audiology, Neurotology &Otology (ADANO), and EAONO (European Academy for Otology and Neurotology).

SENS-401 has received Orphan Drug Designation in Europe for the treatment of SSNHL, and for platinum-induced ototoxicity in pediatric populations in the US.

SENS-401 is Sensorion’s second product candidate to enter Phase 2 for orally-delivered treatment of inner ear diseases. SENS-111, the Company’s first product, is currently evaluated in an international – multicenter, placebo-controlled Phase 2 trial in vertigo caused by acute unilateral vestibulopathy (AUV).

The VHP enables Sensorion to conduct its clinical trial in all European Union countries. This procedure considerably simplifies the trial’s organization, because a single country’s competent authority coordinates requests and interactions between national drug agencies and Sensorion, and issues a joint opinion. Importantly, the VHP allows the trial to be conducted with a single clinical protocol in all European countries involved.

“We are excited to be moving SENS-401 to the next stage of clinical development as a potential first-in-class therapy for the treatment of sudden sensorineural hearing loss. Currently there are no treatments available for patients with SSNHL,” said Nawal Ouzren, Sensorion’s Chief Executive Officer . “ Our second VHP approval demonstrates our team’s capacity to successfully bring drug candidates to the clinical development stage, and advance the development of therapies for patients with debilitating inner ear disorders.”

About SENS -401 SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population.

About Sensorion Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: SENS-111, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.

Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.

www.sensorion-pharma.com

Contacts

Sensorion Nawal Ouzren CEO contact@sensorion-pharma.com   Tél : 04 67 20 77 30 Investor Relations – International LifeSci Advisors LLC Chris Maggos - Managing Director, Europe chris@lifesciadvisors.com Tél. : +41 79 367 6254
   
Libellé : SENSORION Code ISIN : FR0012596468 Mnémonique : ALSEN   Relations Presse Alize RP Caroline Carmagnol & Wendy Rigal sensorion@ali zerp.com  

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on September 6, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 120

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 14

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 127

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 249

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading

Top 5 Most Recently Viewed Articles

Kos Biotechnology Closes Record-Breaking $123M Fund

Updated Category News Views 80

Unprecedented Funding for Life Sciences When you hear about a $123 million fund popping up from nowhere, you stop and take notice. Kos Biotechnology Partners, a name that's bursting onto the scene with a hefty global life sciences fund, isn't messing around. Got their roots sinking into both New York and the ancient soil of Athens—this isn't just some flash-in-the-pan...

Continue Reading
Lyric Advances Battery Technology with Innovative Equipment

Updated Category News Views 149

Lyric's Innovative Contributions in Battery Technology Recently, Lyric successfully shipped its first solid-state battery front-end equipment to a customer, marking a significant milestone in their ongoing advancements in battery production technology. This achievement is a testament to Lyric's extensive experience and deep expertise in the field of solid-state batteries,...

Continue Reading
Danish Stock Market Update: Modest Decline and Notable Movers

Updated Category News Views 226

Danish Stock Market Sees Modest Decline The recent trading session in Denmark concluded with a slight downturn, marking a challenging day for investors as the OMX Copenhagen 20 index closed lower. The end of trading saw the index experiencing a reduction of 0.23%, setting a new six-month low. Such fluctuations can often reflect broader economic sentiments and provide...

Continue Reading
LiTHOS Group Advances Lithium Extraction with New Patent

Updated Category News Views 275

LiTHOS Group Innovates Lithium Extraction Techniques LiTHOS Group Ltd. (CBOE CA: LITS), a leader in sustainable lithium brine extraction, has achieved a significant milestone by securing a U.S. patent. The United States Patent and Trademark Office (USPTO) has allowed their patent for the "Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from...

Continue Reading
Karbach Brewing: Your Ideal Venue for Memorable Celebrations

Updated Category News Views 378

Karbach Brewing: A New Venue for Unforgettable Corporate Events As the festive season approaches, businesses in Houston are searching for the ideal place to host their corporate holiday celebrations. Enter Karbach Brewing, a name that is rapidly becoming synonymous with memorable experiences. This brewery is not just about beer; it offers companies a distinctive setting...

Continue Reading